Scientists developed porous microscaffolds that transform human pluripotent stem cells into functional macrophages by recreating embryonic blood-forming environments. The scaffolds prompt stem cell-derived mesoderm to self-organize into vascular structures resembling early developmental niches, enabling efficient blood cell production with minimal growth factor supplementation. Multi-omics analysis revealed the gene networks driving enhanced macrophage expansion within this 3D microenvironment. This breakthrough addresses a fundamental bottleneck in regenerative medicine: producing therapeutic immune cells at scale. Macrophages are the body's primary cellular defenders, clearing pathogens and orchestrating immune responses, but manufacturing them for clinical use has proven prohibitively expensive and inefficient. The engineered macrophages demonstrated real therapeutic potential by successfully treating drug-resistant pneumonia infections in mice. While promising, this remains early-stage research requiring extensive safety testing and optimization before human trials. The technology represents a paradigm shift from traditional cell culture methods toward biomimetic manufacturing platforms. If successfully translated, this could enable off-the-shelf cellular therapies for infections, cancer immunotherapy, and tissue repair applications where macrophages play crucial roles.